Chapin Davis Inc. Makes New Investment in DaVita Inc. $DVA

Chapin Davis Inc. purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,548 shares of the company’s stock, valued at approximately $1,012,000.

Other hedge funds have also made changes to their positions in the company. Root Financial Partners LLC grew its position in shares of DaVita by 128.0% in the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after purchasing an additional 105 shares during the period. Caitlin John LLC purchased a new position in DaVita during the fourth quarter worth about $34,000. Canada Pension Plan Investment Board acquired a new stake in DaVita in the 2nd quarter worth about $43,000. Compass Financial Management LLC purchased a new stake in DaVita in the 2nd quarter valued at about $72,000. Finally, Sankala Group LLC acquired a new position in shares of DaVita during the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Up 1.0%

NYSE:DVA opened at $180.72 on Friday. The firm’s fifty day simple moving average is $211.96 and its 200 day simple moving average is $183.05. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49. The firm has a market capitalization of $11.53 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 0.46 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.

Insider Activity

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Raymond James Financial set a $220.00 price objective on shares of DaVita in a report on Friday, August 7th. UBS Group upped their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Truist Financial decreased their price target on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Finally, Barclays upped their price objective on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus target price of $221.75.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.